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Abstract
Leukemia is a deadly and common cancer, especially in children and adolescents. The
misdiagnosis and unexpected complications during the treatment are some factors that increase
the mortality rate of leukemia. The goal of our project was to create a device that would quickly
and accurately assess these complications. While there are existing tests that can perform a single
test for either metastasis or sepsis, there are none that can test for both simultaneously and
rapidly. We propose to modify and combine some of these existing microfluidic designs as well
as create a new component to perform a combinatorial assessment. While we were unable to
verify the results, we have designed a device that will potentially meet our goals of testing for
sepsis, severe sepsis, solid-body metastasis risk, major solid-body metastasis risk, lymphoma
metastasis risk, and progression of the primary blood-based cancer (leukemia/lymphoma), from
7.5 mL of blood in just under 2 hours. We believe that this device has the potential to contribute
to the medical field due to its speed and efficiency, especially in a pediatric demographic.
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Chapter 1: Introduction
Cancer is the second leading cause of death globally, accounting for an estimated 9.6
million deaths in 20181. To put this in a simpler perspective, about 1 in 6 deaths is due to cancer1.
However, adults are not the only ones being affected by cancer. Every day, 43 children are
diagnosed with cancer, with an average age of diagnosis of 6 years old2. Pediatric cancer may
only account for less than one percent of all cancers, but that still becomes a number equaling
11,050 children in the United States under the age of 15 being diagnosed with cancer in 2020.
The American Cancer Society states that of these, “about 1,190 children under the age of 15 are
expected to die from cancer in 2020”3, placing cancer as the second leading cause of death for
children under the age of 14, only after accidents3. There may currently be approximately
375,000 adult survivors of child cancer4, but 60% of them will “suffer devastating late effects
such as secondary cancers, muscular difficulties and infertility”4. This is why we will be focusing
on a primarily pediatric demographic. When identified early, cancer is more likely to respond to
effective treatment and can result in a greater probability of surviving, less morbidity, and less
expensive treatment1. While screening and imaging methods can be effective for certain cancer
types, they are not the most accurate and can be prone to error. There are additional hurdles with
diagnosis and treatment, both due to sepsis and the nature of leukemia/lymphoma (hereon
referred to as Blood-Based Cancers, or BBCs). We believe that the solution to this issue is to
develop a liquid biopsy tool in the form of a microfluidic device that is inexpensive to
manufacture, widely distributable, easy to use, gives rapid results, and most importantly can
detect circulating tumor cell clusters (CTCCs), circulating tumor cells (CTCs), BBC white blood
cell (WBC) count, and sepsis biomarkers on a single chip from a single blood sample.
CTCs are cancerous cells that shed from the primary tumor and travel through the
peripheral blood to seed metastasis and form more tumors. They are the primary source of cancer
metastasis. CTCCs on the other hand are fifty-fold more metastatic than CTCs and even rarer5. In
metastatic patients, there may be just 1-2 clusters in a 7.5 mL tube of blood5. One of the
challenges of working with CTCCs is attempting to isolate them without breaking them into
individual CTCs, as most separation methods use enough force to break these clusters apart5. As
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such, very few devices attempt to filter CTC clusters, focusing mostly on standard CTCs. Given
that metastases can be more dangerous than primary tumors, causing approximately 90% of all
cancer deaths6, thoroughly assessing blood samples for CTCs and CTCCs is vital.
The main issue with existing devices that count CTCs or even CTCCs to determine
metastasis is that they ignore BBCs. These cancers are fairly common in children, accounting for
34% of all pediatric cancers7, totaling approximately 4,000 children each year8. They also tend to
not present with solid-body tumors (CTCs), but a dramatic change in WBC count. The typical
WBC count can be between 4,000 - 11,000 per microliter9, but leukemia raises it to 100,000 400,000 per microliter9, and lymphoma can drop it to below 600 per microliter10. In fact, one of
the main types of solid-body tumor that BBCs can present with is leptomeningeal metastasis
(LM), a type of brain cancer metastasis that is difficult to detect, is immune to intravenous
chemotherapy treatment, can be easily mistaken for stroke/behavioral disorders, and can trigger
spontaneous recurrence of typically aggressive brain cancer11. While it is not yet proven to be
linked with LM, brain cancer also accounts for 26% of all pediatric cancers7. Additionally, Stage
3 cancer associated with solid-body tumors (non-BBC), can involve metastasis specifically of the
lymph nodes near the site of the original tumor12. This lymph node metastasis is commonly
known as lymphoma, and can occur before other types of metastasis, which are typically
associated with Stage 4 cancers12. Pediatric Non-Hodgkin's Lymphoma (NHL) has a fairly high
survival rate of between 88%-91%13, depending on the exact age of the patient. Even though
these numbers still equate to between 120 and 160 child deaths in 202013, these numbers do not
account for patients with NHL as a secondary cancer via metastasis. Comparatively, pediatric
leukemia has a lower survival rate of around 47%, or 1,766 child deaths in 202014. This diagnosis
can be complicated greatly by the fact that an abnormal WBC count also occurs in sepsis,
causing a substantial misdiagnosis risk.
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Figure 1.1: Cartoon sketch of the localization of LM tumor in the brain and spine.
Adapted from Ref. F1

Sepsis is a complication of infection, typically characterized by a “systemic inflammatory
response” (SIR)15. It is life-threatening, extremely common, aggressive, and displays a wide
variety of symptoms, depending on the patient. Sepsis can manifest with anything from
cold/clammy skin, abdominal pain, headache, sore throat, chest pain, and many more15. Basically
any symptom of most common diseases, especially infectious diseases, could be an indicator of
sepsis, because it is triggered by infection. This can make it very difficult to detect by physical
symptoms alone. The main symptoms of sepsis can be found within the body. Given that sepsis
is a combination of SIR and an infection, we need to define what each of these are. While there
are several different defining symptoms for SIR, the main one for our device is WBC count,
specifically a WBC count > 12,000/microliter or < 4,000/microliter15. Additionally, we can
define severe sepsis (the second, more deadly phase) as sepsis additionally presenting with a
platelet count < 100,000/mL15. Treatment is split, depending on the diagnosis time. Early
management is implemented within 6 hours of suspected sepsis, and late management within the
next 6 hours15. The ideal window for sepsis diagnosis would be within 6-7 hours of first
occurrence, though sooner is preferred, because the 72-hr survival rate decreases by roughly
7.8% per hour16.
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Another reason that sepsis is so important to detect early is that it can cause long-term
neurological effects if sepsis interacts with chemotherapy drugs. An article by MedPage Today
notes that “the neurotoxic effects of chemotherapy could alter the impact of sepsis on these
patients' neurocognitive abilities”17. These effects include, but are not limited to, a 78% decrease
in spatial planning, a 38% decrease in verbal fluency, a 68% decrease in inhibition, a 39%
decrease in vocabulary, and a 55% decrease in visual processing speed17. Hopefully, close
monitoring can lead to early detection, through which an aggressive treatment can reduce sepsis
risk and reduce the chance of these harmful long-term effects.
We will be testing for all of these conditions within the same chip for several reasons. It
allows for us to detect lymphoma metastasis, as well as assess leukemia progression, solid-body
CTC and CTCC metastasis risk, and sepsis risk. It also allows for us to test for all of these from
the same single vial of blood, rather than up to 3 individual vials. This is better for both time, and
the patient’s well being, as repetitive blood sampling can be hazardous for a child’s health,
especially during cancer treatment. We plan on having this test be available to hospitals during a
child’s treatment, as well as for the 7-14 day window for which they are most vulnerable to
sepsis after treatment, due to a WBC chemotherapy-triggered nadir (drop)18.
With 3D printing technologies becoming more advanced and inexpensive, we hope that
our microfluidic device will be able to be mass-produced at a cheap cost. The main purpose of
designing this multi-step liquid biopsy tool was so that children would have access to diagnostic
tools to improve their prognosis. When designing our microfluidic device, we also considered
the health of our environment. We wanted to help reduce the carbon footprint by making our
device as small as possible, since it cannot be reused. In addition, we wanted our device to be
able to give accurate results as quickly as possible, as current liquid biopsy procedures can take
up to a week to get results, for each test. This device could also be easily modifiable to target
adult BBC, as well as being low-cost enough to be available to low-income communities. We
believe that liquid biopsies will be the answer to improving cancer prognosis, as well as
associated risks, within the child BBC demographic.
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Chapter 2: Project Overview
The goal of our project is to develop a system of microfluidic tests that process a blood
sample in order to assess the relative severity of BBCs and diagnose sepsis. In order to
effectively do this, our project aims to accomplish several distinct and complicated diagnostic
tasks. These tasks include CTC, CTCC, and WBC isolation and quantification. Each of these
diagnostic tasks is completed by one of the three specific sections of the microfluidic system.
The first section of the microfluidic system utilizes a pillar chip design19 to separate clusters of
CTCs from the blood sample in two phases. The first section separates large CTCCs ( >4 cells).
The second section of the microfluidic system utilizes a labyrinth design20 to separate individual
CTCs, small CTCCs, and WBCs from the blood sample. The last section of the chip counts the
number of WBCs which remain in the blood sample and determines the relative expression of
the CD64 protein in order to diagnose and assess sepsis and BBCs within the patient.
The data collection methods for each section of the microfluidic system varies with the
biological component being measured. The first two sections of the system isolate CTC clusters
and individual CTCs within the sample. These cells are rare, and clusters of them even more so,
so the presence of a single cell or cluster is likely indicative of a risk of metastasizing cancer and
therefore the accuracy of the data is important. Both of the first two sections of the microfluidic
system utilize microfabricated electrodes which generate a specific voltage spike based on the
size of the cells, or group of cells, that pass through them. Therefore, this counting mechanism
not only determines the count of CTCs and CTCCs but it also determines the amount of cells that
are present in each cluster during the first section of the system (Appendix A.1). The third
section of the microfluidic system, however, uses both microfabricated electrodes and
fluorescent microscopy in order to measure different aspects of the erythrocytes and leukocytes
within the blood sample. Initially, the same method of microfabricated electrodes is used to
determine the amount of white blood cells present in the sample. After these counted cells are
lysed, the fluorescence from molecular beacons that have specifically bound to CD64 mRNA is
measured with fluorescent microscopy. β-actin mRNA is utilized as a control in this section of
the system due to its consistently normalized expression. The level of β-actin mRNA will be
compared to the level of CD64 mRNA to determine the level of expression for CD64 mRNA.
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Because each molecular beacon can be associated with a specific amount of fluorescence, the
total amount of fluorescence can be utilized to quantify the total amount of CD64 mRNA in the
leukocytes of the sample. The amount of CD64 mRNA and the total erythrocyte and leukocyte
count are used to assess the progression and risk of sepsis for the patient.
In order to effectively assess the severity of BBCs and sepsis all of the quantified
biological levels will be compared to a standard representing a healthy individual. However, for
the first two phases of the microfluidic system, because tumor cells and tumor cell clusters are
being measured, the simple presence of these cells is indicative of problems. Circulating tumor
cell clusters are rare within circulation and are generally created from shedding tumor sites.
Therefore the identification of CTCCs is a significant indicator of tumor sites within the patient.
Individual CTCs are still very rare, but certainly more abundant than clusters. While the
identification of CTCs in a blood sample doesn’t necessitate a tumor, it certainly shows that the
leukemia has progressed significantly and there is danger for metastasis. For the sepsis
assessment and diagnosis section of the microfluidic system, the fluorescence of molecular
beacons bound to CD64 mRNA is measured. The rates of fluorescence increase over time and
the total fluorescence are representative of the CD64 protein expression within the system. The
values of CD64 mRNA expression will be compared to levels of expression within healthy
individuals in order to assess the progression and risk for sepsis.
One of the reasons we wanted our integrated diagnostic test to be composed of
microfluidic chips is because they are inexpensive and easy to manufacture. After considering
the different fabrication methods typically used to create a master mold for the fabrication of
microfluidic devices, such as photolithography and 3D-printing, we decided that 3D printing was
the most convenient method to use. Recent advancements in 3D-printing technologies now allow
for highly complex microfluidic devices to be fabricated via single-step, rapid, and cost-effective
protocols. Using 3D-printing for our mold fabrication method enabled us to rapidly design
different device iterations in the development stage. Our original timeframe and budget for this
project was $1,500 and approximately 30 weeks. However, due to some necessary changes
regarding the current health crisis and associated logistical difficulties, we were forced to
drastically revise our project. These changes shortened our timeframe down to approximately 4
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weeks and a budget of approximately $250. Due to this, our project is largely literature based,
with theoretical data formed from the papers that were the inspiration of our design.

Chapter 3: Background and Significance
3.1 Background and Motivation of Subject Matter
Cancer is a disease caused by genetic mutations that lead to excessive cell division,
abnormal cell growth, and extended lifetime of cells. These genetic mutations cause large
growths of cancer cells called tumors which interfere with natural bodily functions and
commonly lead to death. These massive growths of cells can also spread to other parts of the
body when cells from the tumor shed off of the cell and move around the body, as illustrated in
Figure 3.1. Studies modeling the shedding of tumor cells in rats have shown that millions of
these cells can break off of the tumor everyday. After breaking off of the primary tumor, the
majority of these cells enter blood or lymphatic vessels and end up circulating around the body.
Luckily, these cells do not survive very easily in the environment of circulating blood due to the
lack of growth factors, physical stress, and the unfulfilled necessity of attaching to other cells.
The majority of these cells do not survive the transportation process. However in some cases,
these tumor cells will remain attached to each other and enter the bloodstream as a unit of many
different cells. When tumor cells attach to each other in this manner, their likelihood of surviving
transportation through the blood is significantly increased. This is because clusters can withstand
shear forces of circulation better than single cells and are also resistant to immune attacks. The
cells that do eventually exit the bloodstream and attach themselves elsewhere in the body can
begin to form secondary tumors. This process is called metastasis, and the mobile cancer cells
are called circulating tumor cells (CTCs). The diagnosis of cancer includes blood tests, x-rays,
CT scans, and endoscopy however usually by the point that these tests have a definitive answer
the disease has progressed significantly. In addition, metastasis is generally only discovered
when tumors in other locations around the body begin to grow and are detected21.
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Figure 3.1: Cartoon sketch depicting CTC and CTCC mechanisms of movement in a
blood vessel from a primary tumor. Adapted from Ref. F2

A novel way of diagnosing cancer and metastasis includes the separation and isolation of
CTCs from a blood sample. Tests such as these have been found to have very high efficiencies of
separating CTCs from blood samples. In addition, some of these methods have been very
effective in separating low concentrations of CTCs in blood. Because the average concentration
of CTCs in blood is roughly 5 cells per 10 mL, these methods have to be very effective and
specific in order to achieve usable estimates.
There are various methods currently being used for the separation of CTCs from blood.
These methods include positive and negative immunomagnetic enrichment, microfluidic
immunocapture, and microfluidic filtration. Positive and negative immunomagnetic enrichment
uses antibodies to separate CTCs from a whole blood sample. Positive immunomagnetic
enrichment utilizes antibodies which tend to selectively bind to CTCs and separate them from the
whole blood sample. There are various ways this method has been approached, yielding roughly
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75%+ separation efficiency from various studies. Negative immunomagnetic enrichment also
uses antibodies, however it attaches to other cells present in the sample only leaving CTCs
within the mixture. Microfluidic immunocapture utilizes platinum electrodes for enumeration of
CTCs and also flows the cells into a chamber where they are captured with heterogeneously
bound antibodies. Lastly, is microfluidics for CTC filtration which utilizes the difference in
physical properties of cells to filter them21.

3.2 Microfluidics
Microfluidics is the science of fluids and particles on the scale of micrometers, or
1*10^-5 meters. Using microfluidics allows for reduced volumes of both samples and reagents,
lower cost, higher sensitivity and portability, the ability to be automated, the ability to use
size-based separation techniques, and the ability to precisely control the flow rate. One of the
main ways of controlling flow through microfluidic channels comes through layering a control
layer on top of the flow layer and filling it with water or buffer to stop the flow, much the same
as stepping on a garden hose.
Inertial microfluidics is a simpler, more passive design that allows for precise
manipulation and high throughput using a relatively simple structure. In inertial microfluidics,
particles in a straight channel laterally migrate to different equilibrium positions, known as
inertial migration. In fact, this phenomenon is particularly relevant to microfluidics, due to the
particle size ratio to the dimensions of the channels. The inertial migration exists due to the
counteraction of the shear gradient lift force and the wall lift force. Gradient lift force is from the
curvature of the fluid velocity profile and how this curvature interacts with a particle, directing
said particle towards the wall of the channel. Wall lift force is from the flow field interaction
between the particle and the walls, repelling the particle from the wall.
Another major component of inertial microfluidics is secondary flow, where the fluid
near the center of the channel has a higher momentum than that near the wall. This creates
counter-rotating streams, which can create additional viscous drag forces on particles
perpendicular to the main stream. These two components together allow for particle separation
based on size, the foundation of this paper22.
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3.3 Labyrinth Microfluidic Device for CTC Filtration
The design of this device was inspired by the Labyrinth in Greek mythology that was
designed and built by Daedalus for King Minos of Crete to hold the Minotaur. The elaborate
structure, with its numerous turns and corners, is perfect for size-based enrichment of CTCs by
bulk depletion of hematopoietic cells using inertial microfluidics-based separation. CTCs are
isolated from other blood cells in curved microfluidic devices by focusing different sized cells
into different streamlines and collecting them into individual outlet channels. The inertial force
focuses the particles, while the drag force from Dean flow causes particle migration away from
the center of the channel23.
As the particles are injected from the inlet of the channel, they immediately equilibrate
into two broad bands near the longer channel wall under the influence of shear lift (FS) and wall
lift forces (FW) acting vertically with respect to the channel height. When the flow velocity is
relatively low, particles migrate laterally towards the center equilibrium due to a rotation lift
force (FR), forming two focusing streaks. As the flow velocity increases, the two streaks start to
migrate towards the inner channel wall, followed by a single point focusing at a particular
threshold due to the differential interplay between the net lift force (FL) and the Dean drag force
(FD). Outer wall migration is induced as the flow velocity is increased above this threshold24.
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Figure 3.2: Visual representation of the Dean coupled inertial focusing profiles of particles in
a curved low aspect ratio microchannel. Adapted from Ref. F3.
The relationship describing the magnitude of lift force (FL) is the following:

FL =

μ2
p

Re2pfc (Rec , xc ) ,

Eq. 3.1

where Rep is the particle Reynolds number, Rec is the channel Reynolds number, and xc is the
position of the particle within the channel24.

The expression for drag force (FD) is given by:
FD ~ pU2maD2hr-1,

Eq. 3.2

Where Um  is the maximum channel velocity, a is the particle diameter, Dh is the hydraulic
diameter, and r is the radius of curvature of the channel24.
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Using these two equations, a new equilibrium position can be estimated from the ratio of FL to
FD:
FL
FD

=

1
δ

( Dha ) 3 Renc , (n<0),

Eq. 3.3

Where δ is the curvature ratio24,

δ=

Dh
2r

Eq. 3.4

It has been proposed that sharp curves enhance the focusing of smaller particles, which is the
reason why our microfluidic device must contain curves with a high curvature ratio25. What
differentiates the labyrinth design from typical spiral designs is the fact that labyrinths have
numerous sharp corners placed across the flow pattern. The sharper curvatures achieved by these
corners enhance Dean forces to migrate particles toward their equilibrium positions, resulting in
clean separated focusing of both large CTCs and small WBCs24.

Figure 3.3: SEM image of sharp corners in Labyrinth that enhance Dean forces. Adapted
from Ref. F4.
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3.4 Sepsis and Mechanism of Propagation
Every year there are approximately 50 million cases of sepsis resulting in 11 million
deaths. Sepsis presents with increased temperature, respiratory rate, CO2 levels in blood and
abnormal WBC count. Because these symptoms are common in many diseases diagnosing sepsis
can be extremely challenging. In addition, the death rate for sepsis increases by 7.8%25 every
hour which means that prompt diagnosis is essential.Sepsis is an inflammatory autoimmune
disease which is triggered by an infection or cancer. When pathogens or CTCs enter the blood,
they are recognized by white blood cells and trigger an immune reaction. This immune reaction
entails an exponential increase in the release of inflammatory chemokines and the recruitment of
WBCs, causing significant tissue and organ damage. The cell that plays the largest role in this
process is the neutrophil. The neutrophil is the most abundant white blood cell in the body which
propagates inflammation through the degranulation of inflammatory chemokines. These
chemokines attract other WBCs which continue the signal propagation. During this inflammatory
process, neutrophils also release NETs (neutrophil extracellular traps) of chromatin and serine
proteases with the biological intention of combating pathogens from spreading and replicating.
However, excessive NET formation leads to intravascular coagulation and thrombosis. In
addition the excessive amount of inflammatory chemokines can leak out of blood vessels and
disrupt natural organ function. All of these factors, with their significantly increased abundance
during sepsis, cause tissue damage and eventually organ failure.
The transmembrane protein utilized by neutrophils for the recognition of pathogens and
CTCs is CD64. During sepsis, this protein is heavily upregulated as the cells attempt to increase
their efficacy of pathogen recognition. CD64 is a commonly used biomarker for diagnosing
sepsis because its expression increases as the severity of the disease worsens. During sepsis and
similar inflammatory events, CD64 can be upregulated by a factor of 50 when compared to
normal levels of the protein allowing for easily distinguishable diagnosis.
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3.5 Molecular Beacons for the Enumeration of mRNA

Figure 3.4: Sketch of the binding mechanism for molecular beacons, with the unbound
beacon shown on the left and the bound beacons shown on the right.

Molecular beacons are a designed group of molecules commonly used in PCR and qPCR
for the enumeration of DNA replicated in the procedure. A molecular beacon is composed of a
fluorophore, a quencher, and an oligonucleotide strand as shown in Figure 3.5. The
oligonucleotide is engineered to be antisense to the target DNA or mRNA so that it can bind
specifically. When the oligonucleotide strand of the molecular beacon binds to the target
molecule, the fluorophore becomes separated from the quencher molecule and becomes active.
The active fluorophore will then fluoresce when light within a small range of wavelengths makes
contact with it. This light excites electrons within the fluorophore which releases energy in the
form of photons during de-excitation. The amount of released light from each fluorophore is then
measured utilizing fluorescent microscopy to achieve a quantifiable amount of nucleotides
within
the solution.
Figure 3.5 represents a single fluorophore molecular beacon, however, recent
developments have resulted in the creation of molecular beacons which have multiple
fluorophores and quenchers resulting in a much stronger signal from the sample. The most
commonly used multiple fluorophore molecular beacons are composed of three fluorophores
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with their respective quenchers. These novel molecular beacons are able to produce fluorescence
at rates up to 320 times larger than single fluorophore molecular beacons as shown in Figure 3.6.

Figure 3.5: C
 artoon sketch of a triple fluorophore/quencher molecular beacon shown
on the left, with a graph of the relative fluorescence of different molecular beacon designs on
the right. Adapted from Ref. F5

Chapter 4: Subsystems Overview
4.1 Pillar Chip
The cluster separation segment of the system occurs first because the flow rates which
occur in the Labyrinth design are high enough to break up the clusters and lower the efficacy of
the diagnosis. The mechanism for cluster separation is deterministic lateral displacement (DLD),
in which groups of cells are horizontally displaced based upon size and asymmetry. The process
occurs in two phases, both of which separate different sizes of clusters based on different
qualities of the clusters. Due to the redundancy of Stage 2 isolating small CTCs as the labyrinth
does the same, as well as the large time requirement (~6 hours), we decided to focus on Stage 1.
Further information on Stage 2 can be found in Appendix section A2.
The first phase of the cluster separation design is focused on separating large clusters of
cells (4+ grouped CTCs). This process works by flowing cells and clusters through many sets of
slightly displaced rows of vertical pillars. Small clusters (<4 grouped CTCs) are able to simply
weave through the rows of pillars and therefore move only vertically. Large clusters of cells,
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however, are not able to weave through the pillars and are therefore displaced laterally as well as
vertically as they move through the pillars of cells. This results in the small clusters and single
CTCs being directly vertical of where they entered the chip and the large clusters being slightly
laterally displaced. There are two outlets from the first phase of the chip, one directly below the
blood entrance flow which collects small clusters and single CTCs, and one on the opposite side
which collects large clusters.

Figure 4.1: C
 artoon sketch diagramming the mechanism of large cluster separation through
deterministic lateral displacement.  Adapted from Ref. F6

In order to separate large clusters, we decided to use the first section of the pillar chip
design. As the cells enter the microfluidic system, the large clusters, which contain 4 or more
cells, will be isolated through deterministic lateral displacement. These large clusters of cells will
be forced to move diagonally through the system as they flow down through the rows of slightly
offset pillars. The large clusters are collected on the right side of the chip, and will later be
counted utilizing electrode cell counters. The small clusters and single cells will flow into the
labyrinth section of the microfluidic system. The expected capture efficiency of this step is
~99%, and the flow rate being utilized is 16.6 ul/min. Initially we were planning on utilizing two
stages of the pillar design to separate both large and small clusters but the run time for the chip
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designed to separate small clusters was ~6 hours, and this took too long for our goal of having a
< 2 hour runtime.

 igure 4.2: Cluster separation microfluidic chip AutoCAD design with blood and
F
buffer entering through the top of the chip and separated clusters exiting on the bottom right.
4.2 Labyrinth Chip

Figure 4.3: Long loops and sharp corners in Labyrinth result in clean and separated focusing
of CTCs and small WBCs. Adapted from Ref. F4.
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Figure 4.4: Labyrinth chip AutoCAD sketch with extra valve to pump buffer into the inlet.
Color added to illustrate layer differentiation based on component height.
Now that the CTC clusters have been captured and the individual CTCs funneled into the
inlet of the Labyrinth, we will have to increase the flow rate of the sample fluid from the CTC
cluster separator that operates between 10-40 µL/min to 1800–2600 µL/min. We will
accomplish this by having a separate valve connected to the inlet injecting buffer at a flow rate of
1800-2600 µL/min, mixing with the sample fluid from the cluster separator. The reason we need
to increase the flow rate so drastically is so that we generate enough inertial lift forces and Dean
flow drag forces to focus and separate the cells by size. The inertial force focuses the cells in the
channel, while the drag force from Dean flow causes the cells to migrate away from the center of
the channel, resulting in size-based separation27. Another benefit of adding the extra valve to the
input of the valve is the fact that this valve could be used to pre-flow the device with 1%
Pluronic acid solution (diluted in 1X PBS) at 100 μL/min for 10 minutes, followed by an
incubation time of 10 minutes27. This step needs to be performed to prevent the cells from
clotting on the channel walls27. It could be performed as the blood sample is being processed
through the cluster separator. The total channel length of the Labyrinth is 637 mm, it is 500 µm
in width, 100 µm in height, and consists of 11 loops and 56 corners27. The loops, which have a
small curvature ratio, provide enough length of channel to achieve total focusing of cells and to
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have the proper curvature for the separation of CTCs and blood cells27. The 56 sharp right-angle
corners, which have high curvature ratio, further enhance the focusing of smaller cells27. The
channel expands from a width of 500 µm to 1000 µm before diverting into four separate outlets
to collect WBCs, CTCs, RBCs and other blood components27. The outlet that contains the WBCs
from the Labyrinth will be redirected to the CD64 positive neutrophil sepsis test.
The reason the authors wanted to develop a label-free isolation method is because many
microfluidic devices rely on positive or negative selection to isolate CTCs, such as the
immune-affinity capture method that utilizes antibodies to target molecules, such as the epithelial
cell adhesion molecule (EpCAM), which are expressed exclusively on tumor cells27. The
drawback with these methods however, is that not all CTCs express EpCAM, and downstream
single cell-analysis of captured CTCs can be challenging due to complex protocols that may
interfere with RNA stability during the release step of CTCs from devices27. They also wanted to
address the drawbacks of using conventional curved channel or spiral channel microfluidic
devices, because these devices are less successful at focusing small cells such as WBCs27.
Stronger mixing forces are required to move smaller cells to equilibrium positions and achieve
better focusing of these particles, which can be proven by looking at the expression for the
inertial lift force27.

Figure 4.5: Inertial lift force equation showing that the magnitude of the inertial lift force is
proportional to the fourth power of particle diameter, which proves that smaller
particles are harder to focus. Adapted from Ref. F7.

As you can see in Figure 4.5, the inertial lift force (FL) is proportional to the fourth power
of particle diameter (ap), which means that smaller particles experience smaller inertial lift
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forces. This is the reason why most spiral devices have to compromise for either low CTC
recovery or low WBC removal as the smaller cells are not efficiently focused27. However, by
designing the Labyrinth with sharp corners across the flow pattern, the authors were able to
enhance Dean forces to migrate particles toward their equilibrium positions while retaining clean
separated focusing of both large CTCs and small WBCs27. The percent recovery in outlet 1
during one of the control experiments was 91% for WBCs, and in outlet 2 the percent recovery
was 92% for PANC-1 cells, 90% for H1650 cells, and 91% for MCF-7 cells to list a few cell
lines27.
A separate research team developed and optimized a novel Labyrinth microfluidic device
to efficiently isolate CTCs from peripheral blood of Hepatocellular Carcinoma (HCC) patients28.
They made modifications to the original Labyrinth and increased the height of the channel to 110
µm. This modification increased the Dean force effect, allowing the cells to equilibrate at similar
focusing positions at lower flow velocities, which reduced the overall shear stress acting on the
CTCs during separation. The Labyrinth device has an inlet to inject the sample, and four outlets.
Outlet 1 collects WBCs, Outlet 2 collects CTCs, and Outlets 3 and 4 were included to reduce the
sample fluid volume after cell separation and collection. Spike-in experiments to determine the
recovery rate of CTCs in Outlet 2, at the determined optimal flow rate of 2000 µL/min, revealed
a recovery rate of 91.17% and 95.69% for Hep 3B and Hep G2 cells respectively after
considering only the cells with a size above the cut-off cell diameter entering the outlet28. The
WBC depletion rate at this optimal flow rate was determined to be 97.66 ± 0.53%. After
optimizing the flow rate of the Labyrinth with spike-in experiments, the researchers tested the
device with peripheral blood from HCC patients, and identified CTCs in 88.1% of the patients
over different tumor stages 28
 . Interestingly, they also found that 55% of the patients had the
presence of circulating tumor microemboli (CTM), sometimes referred to as circulating tumor
cell clusters (CTCCs)28.
While we didn’t make drastic modifications to the Labyrinth device, mainly because it is
already highly efficient at separating CTCs and WBCs, the integration of the Labyrinth into a
full metastasis test that also detects CTC clusters and CD64 positive neutrophils will have
important value for its clinical application.
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4.3 CD64 mRNA Expression Chip
The sepsis diagnosis system within our senior design project is designed to quickly and
effectively quantify the expression of the CD64 transmembrane protein for sepsis diagnosis. This
step occurs directly after the CTC separation that takes place within the labyrinth design. This
process occurs in 5 steps, including the enumeration of leukocytes and erythrocytes, the lysing of
the patient’s leukocytes, the mixing and binding of the Molecular Beacons to CD64 mRNA and
β-actin mRNA, the fluorescent microscopy of the bound CD64 mRNA, and finally the data
interpretation. After the CTC separation within the labyrinth chip, the remaining cells will
primarily be composed of leukocytes. These leukocytes include neutrophils and monocytes, both
of which present the CD64 transmembrane protein. The mRNA that encodes the CD64 protein
can be quantified in order to determine total CD64 expression and diagnose the severity of
sepsis.
In order for efficient access to this mRNA, which is located in the cytoplasm, the
leukocytes will be lysed with a lysing buffer composed of water, NH4CL, KHCO3, and
Tetrasodium EDTA29. Initially, there was a concern as to the availability of the CD64 mRNA
however certain studies have shown that there is a significant upregulation in CD64 mRNA
during events of inflammation within the body30. These significantly increased levels of mRNA
will not only be numerous enough to be imaged, but their levels of upregulation will provide a
significant amount of information in regards to the severity of the inflammation.
The lysed cells then enter the rotary chip. As they enter the rotary chip they will be mixed
with the engineered molecular beacons. The engineered molecular beacons will utilize MPQ3 as
the fluorophores in addition to a triple quencher/fluorophore site in order to receive a stronger
signal from the labeled mRNA31. This MPQ3 triple fluorophore site has been shown to produce a
fluorescence that is significantly stronger than single fluorophore/quencher siges. These
fluorophores will only become active after the oligonucleotide sequence has specifically bound
to the CD64 mRNA. In addition to the CD64 targeted molecular beacons, molecular beacons
targeting β-actin will be used. These molecular beacons will utilize a similar triple
quencher/fluorophore site, however BHQ2 will be used instead of MPQ3 in order to differentiate
between the fluorescence from each mRNA. These β-actin mRNA targeting molecular beacons
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are utilized to determine a control level of mRNA expression and will provide a non-upregulated
point of comparison to determine the level of expression for CD64 mRNA. As shown in Figure
4.4, the molecular beacons and the lysed WBCs will enter the chip. In order to facilitate the
mixing and proper binding of the solutions, oscillating pressures within a circular path are
applied.
From this point on fluorescent microscopy is being applied to the mixture and the
photons produced after MPQ3 and BHQ2 excitation will be measured. Because each fluorescent
beacon corresponds to a specific amount of reflected light, the total amount of reflected light can
be used as a method of quantification for the labeled CD64 and β-actin mRNA. After the mixture
flows out of the mixing circular path, it enters a reservoir which is also under fluorescent
microscopy. The mixture that enters this reservoir will remain there as the rest of the molecular
beacons are mixed.
Finally, the fluorescence data must be interpreted. The MPQ3 fluorophores and the
BHQ2 fluorophores will fluoresce with light that has wavelengths of 485nm and 600nm
respectively. The released photons from each of these fluorophores will also vary in wavelength.
The measured levels of fluorescence for each of the fluorophores will then be compared to get
quantitative amounts of expression for both CD64 mRNA and β-actin mRNA. These expression
levels will then be compared in order to determine the severity and stage of sepsis. In
inflammatory diseases, CD64 expression can increase up to a factor of 50. Therefore, depending
on the difference of fluorescence magnitude of each wavelength, the severity of sepsis can be
quantified30. Based upon the increase in fluorescence over time and the total fluorescence, total
CD64 mRNA can also initially be estimated and later fully quantified. Depending upon the rate
of increase in fluorescence it is possible to estimate the total amount of CD64 mRNA in the
sample. If the measured fluorescence is increasing very quickly, it is indicative of a large amount
of CD64 mRNA in the sample. While this estimation may not be quantitative, it can save a
significant amount of time during sepsis diagnosis and potentially allow the early administration
of treatment for sepsis which can potentially save the patient’s life.
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Figure 4.6: AutoCAD diagram of sepsis assessment in the microfluidic system with lysing and
quenching pictured on the top in green, the mixing channels pictured in the middle in red, and
the imaging reservoir pictured on the bottom in green.

Chapter 5: System Integration

Figure 5.1: AutoCAD design showing full system integration of the various components and
control layer based chamber isolation.
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For our device, we have several different components working together to analyze
different common cancer complications. Once we finalized designs for each of these individual
components, the next major step was putting all of them together. This came with a few
additional challenges, in that not all of the components were of similar size. Given that the
Labyrinth was the largest of the components, we had to resize some of the components to be able
to hold the same volume of blood sample as the Labyrinth. We resized the components that were
not size dependent for their operation, specifically the sepsis fluorescence device. Once we were
able to properly resize all of the components, our final device size was 23.5 cm x 18.7 cm x 110
µm (blue layer) or 90 µm (green/red layer). While we considered different component
arrangements for our device, we decided on starting with the cluster device, as the clusters are
the most fragile biological component that we are measuring. Additionally, we decided that the
sepsis analyzer should be last, given that it lyses the WBCs, so they cannot be used for other
tests. If we put the sepsis analyzer leading directly from the WBC output of the Labyrinth, we
would also be able to drastically reduce the sample size by only using the necessary blood
components. This leads us to our next major issue.
Once we had all of the components put together, we found that the overall time it would
take for a 7.5 mL sample to run through was 17.03 hours, or 17 hours and 2 minutes . This was
far too long, so we looked for ways to reduce the time for our test. Our first major solution was
to utilize the Labyrinth’s ability to separate blood components and only run the WBCs through
the sepsis analyzer. WBCs take up less than 1% of blood, which greatly reduced the test volume
for this component, as mentioned above. This alone reduced our full testing time to 8.35 hours,
or 8 hours and 21 minutes. This was still not good enough for us, so we decided to remove the
second stage of the cluster separator that separates small CTCCs. Given that it only had
approximately 65.5% efficiency in removing small CTCCs, and the Labyrinth has also been
observed to have the ability to separate small CTCCs, we decided to remove it, which reduced
the total test time further to 1.86 hours, or 1 hour and 52 minutes. While our goal was for the test
to take less than two hours, we could not find any other way to reduce the test time without
significantly affecting efficiency. For example, reducing the overall test volume would reduce
our time by approximately 8 minutes per 0.5 mL, but given the rarity of CTCs and CTCCs, we
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felt that reducing the volume could negatively impact our test’s efficiency. We are satisfied with
our testing time because it is significantly better than that of a standard blood culture test to
diagnose sepsis, which can take several days to send to a lab, process, and receive the results.
Once the time issue was resolved, and the design was completed, we were able to resolve
our next issue, which was the fact that the different components of our device required varying
flow rates and test volumes. Test volumes were easy to fix, by sizing up the sepsis analyzer to
allow for a larger sample to be analyzed, and allowing for more time for the cluster separator,
which was factored into the above calculations. We were able to resolve the flow rate issue by
adding buffer valves to inject additional buffer at higher rates of flow leading into the Labyrinth
(highest flow rate), and increase the microfluidic pipeline diameter leading into the sepsis
analyzer (lowest flow rate), which was also slowed due to the small percentage of the total
volume being comprised of WBCs.

Figure 5.2: Different labeled subsections with flow rates or stop times, with highlighted valve
for Labyrinth flow rate increase.

We were then able to add components to the full test, however due to the current health
crisis, we were not able to practically incorporate these components, so this section will be
largely theoretical. The main components to be added were electrode-based counters to read the
outputs for each component. They would be two electrodes with a current between them, and
when a biological component passes between them, there is a noticeable impedance correlating
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to what and how much is passing through. We would place these counters at the end of stage 1 of
the cluster separator to count large CTCCs, and at the end of the Labyrinth to count blood
components (specifically WBC and platelets, for leukemia/lymphoma, and severe sepsis,
respectively). We would set thresholds within the code for these counters correlating to
dangerous levels for each component. Any of the following levels would trigger a “yellow”
warning, correlating to low risk: WBC < 30,000,000 or > 90,000,000 for sepsis32, WBC <
4,500,000 for lymphoma33, WBC > 7,500,00,000 for leukemia34, CTC > 0 for metastasis, or
CD64 mRNA expression >20 fold difference when compared to patient control for sepsis
(discussed later). A “red” warning would be triggered by any of the following levels: platelet
count < 750,000 for severe sepsis32, or CTCC > 0 for severe metastasis. These numbers correlate
to a 7.5 mL blood sample, and will vary depending on how much blood is tested. We would also
add a fluorescent imaging device and associated program to automatically count the mRNA
biomarker in the WBCs for sepsis. The rest of the components that we would need to add would
facilitate automation of our device, including a valve automation program to create different flow
rates for the necessary input chemicals and buffer, a needle array for the input/output valves, and
associated holding tanks for input, output, buffer, and all necessary chemicals.

Chapter 6: Results
Because we were unable to perform our own experiment due to the unavailability of lab
space, we utilized example data from articles we explored in our literature review. Due to the
multifaceted nature of our device, there was no single study which we could draw all of our
hypothetical data from. Instead, we utilized data from several different articles which was
applicable to specific sections of our microfluidic system and interpreted it as we would if the
data had been collected from our device.
6.1 Hypothetical Pillar Data35
The utilized cluster data was taken from a study titled “Quantitative flow cytometric
identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma.” The
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purpose of the study was to perform survival analysis of patients with stage III/IV lymphoma to
determine what effect clusters had on death rate. The study utilized 61 blood samples from 28
patients with late stage lymphoma and analyzed them for the presence of clusters by utilizing
flow cytometry. Out of the 28 patients, 17 (61%) presented with a significant amount of aberrant
clusters. In addition, the study found a significant association between aberrant cluster presence
and increased death rate at a 95% confidence interval (P = .0227).
In the context of our microfluidic system, having 61% of patients presenting with
aberrant clusters is very high. The target population of our microfluidic system is not patients
who are already in late stages of lymphoma or leukemia, instead our device is targeted towards
the at risk population and early stage cancer patients. Therefore, we would expect to see a
significantly lower percentage of patients with circulating tumor cell clusters. The presence of
circulating tumor clusters in a patient indicates that either metastasis has already occurred or
there is a very high danger of successful metastasis. This information could be essential to a
physician when prescribing treatment to a patient due to the fact that cluster presence indicates a
severity of cancer which can not be shown through normal testing. In addition, cluster presence
has been shown to have a significant association with an increase in death rate. Therefore, after
the presence of clusters is detected, the severity of chemotherapy and associated drugs should be
increased in response.
6.2 Hypothetical Labyrinth Data36
The only study with data relevant to the Labyrinth section of our device is “New
Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell
Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma.” The research team
evaluated the total number of CTCs in blood samples from 42 HCC patients and 5 non-HCC
healthy control subjects. According to standard AJCC TNM staging, 26 (61.9%) of the HCC
patients were stage II or above, and multiple nodules were observed in 19 (45.2%) of the HCC
patients. It was also evident from the radiographs of 10 of the patients (23.8%) that
macrovascular invasion was present. After gathering this information from the patients, the
researchers finally processed the blood samples of the HCC and control patients to see if there
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was any correlation between the presence of CTCs/CTCCs and tumor metastasis. They used IF
analysis to identify CTCs as CD45 negative and HCC marker positive cells with intact nuclei
stained by DAPI. In the HCC patients, they detected anywhere between 0.4 to 8.7 CTCs/mL
(mean = 3.36 ± 0.31 CTC/ml, n = 42) , which was significantly higher than that from the
healthy control patients ((mean = 0.53 ± 0.1 CTC/ml, n = 5) (p = 0.0001). It was also
observed that patients with higher TNM stages, stages II-IV, had higher numbers of CTCs (3.73
CTCs/mL, n = 26) than lower TNM stage patients, stages 0-I (2.76 CTCs/mL, n = 16).
Unfortunately, the difference in CTC numbers between the two cohorts was not statistically
significant (p = 0.1258). Of the 10 patients who presented with macrovascular invasion, 100%
of them were positive for CTCs. In the other 32 patients that did not present with macrovascular
invasion, 84.4% had detectable CTCs. The data did not reach statistical significance because
there was a limited number of patients with macrovascular invasion (p = 0.1829). CTM were
also observed among the CTCs isolated from the HCC patients, with numbers ranging from 0 to
1.29 CTM/mL in all stages of HCC (mean = 0.19 ± 0.04, n = 42). CTM were not observed in
any non-HCC control subjects (n = 5). Supporting the fact that CTM are more metastatic than
single CTCs, the researchers found that the number of CTM was significantly higher in more
advanced TNM stage patients (mean = 0.26 ± 0.06 n = 26) than that of early TNM stage
patients (mean = 0.08 ± 0.03, n = 16) (p = 0.0172).
The most important takeaway from this data is that the number of CTCs and CTM was
higher in more advanced TNM stages, which suggests that there is a link between these cancer
cells and tumor metastasis. The Labyrinth data is important for our application because one of
the main types of solid-body tumor that blood based cancers can present with is leptomeningeal
metastasis. Our hope is that our device would be able to detect this metastasis in the early stages,
improving patient survival. Additionally, Stage 3 cancer associated with solid-body tumors can
metastasize into lymph nodes near the site of the original tumor. This lymph node metastasis is
otherwise known as lymphoma. Our goal with this device is to be able to detect metastasis from
solid-body tumors before it has the opportunity to reach the lymph nodes and turn into
lymphoma.
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In our case, data collection for CTCs and small CTC clusters would have involved
flowing in the sample from the pillar chip, which at this point would have already separated large
clusters from single CTCs, small clusters, and WBCs, into the inlet of the Labyrinth. After
collecting the single CTCs and small clusters from outlet 2, we could stain the cells and perform
fluorescent microscopy to take images of the cells as seen in Figure 6.1 and Figure 6.2,
allowing for a CTC and cluster count, differentiation between CTCs and small clusters, and
visualization of cell morphology. Several studies have already confirmed that the number of
CTCs as well as their phenotypic changes in response to treatment can provide useful
information to oncologists for individual treatment. Higher CTC counts often correlate with
lower overall survival rates, and phenotypic changes can indicate acquired drug resistance.

Figure 6.1: Stained CTCs isolated from HCC patients. Adapted from Ref. F8.
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Figure 6.2: Stained CTM isolated from HCC patients. Adapted from Ref. F8

6.3 Hypothetical Sepsis Assessment Data37

Figure 6.3 Graph representing the difference in expression of β-actin mRNA, labeled as
control, and CD64 mRNA, labeled as inflamed NR, in inflamed and non- inflamed tissue.
Adapted from Ref. F9

37

The utilized sepsis analysis data was taken from a study titled “Fc gamma receptor CD64
modulates the inhibitory activity of infliximab”. This study was focused on assessing the efficacy
of anti-TNF antibodies on inflamed tissue. Their method of assessing and determining why the
drug may not be working as expected included the measurement of CD64 mRNA in inflamed
tissue. The researchers hypothesized that the excessive CD64 expression counteracted the
anti-inflammatory mechanism of anti-TNF antibodies. During their experiment, they measured
CD64 mRNA expression compared against β-actin mRNA which was utilized as their control.
The study found that during significant inflammation, CD64 mRNA is expressed more
than β-actin mRNA by a factor of >50 as shown in Figure 6.3 (P <.001). This comparison of
expression between CD64 mRNA and β-actin mRNA which resulted in such a significant
difference in expression is similar to the data we would expect to achieve from our sepsis
analysis system. Such an increased expression of CD64 mRNA is indicative of severe
inflammation, and a similar upregulation would be observed in sepsis. For our testing,
upregulation of CD64 mRNA greater than β-actin mRNA by a factor of >20 would be indicative
of sepsis and require immediate treatment. In addition, this study found that the upregulation of
CD64 mRNA resulted in decreased efficacy of anti-inflammatory drugs. This finding solidifies
the necessity of early sepsis diagnosis because as the disease progresses, it not only becomes
more deadly at a high rate, but it also becomes more challenging to treat. For this reason, we
decreased the testing time of our microfluidic system by as much as possible so as to gain an
understanding of the patient's situation before the disease progresses excessively.

Chapter 7: Engineering Standards
7.1 Manufacturability
Due to the microfluidic nature of this device, the manufacturing process is significantly
facilitated. The majority of this device can be created by 3D printing molds of each section and
then filling them with PDMS to create the actual microfluidic device. The molds will be created
based upon the height of each microfluidic section, then after filling, each section with varying
height will be stacked in order to create the full microfluidic system. Some parts of the system,
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however, can not be 3D printed and will instead be bought separately and then introduced to the
system. These parts include the electrode cell counters, the fluorescence imaging device, and
extra microfluidic parts such as pipettes and pumps. In addition, every part of the system making
contact with the blood is biologically inert and will be sterilized prior to introduction of blood.

7.2 Environmental/Sustainability
Given that our integrated liquid biopsy microfluidic chip is only 23.5 cm x 18.7 cm x 200
µm in length, width, and height respectively, it does not produce as much waste as standard
label-based CTC capture protocols or sepsis blood culture tests. Laboratories and healthcare
facilities already contribute greatly to the plastic waste generated with single-use plastic
materials such as pipettes, culture flasks, test tubes, etc., so we did not want our device to add too
much to the waste burden. Additionally, since our device uses very small volumes of liquids, it
cuts down on the chemical reagents that need to be properly collected and disposed of in
hazardous waste facilities.

7.3 Economic/Social/Political
Mass-manufacturing of our device would help drive down the cost of a single unit, and as
a result would make it more accessible to the communities that need it the most, mostly children
in developing countries. According to patient case records of children with acute lymphoblastic
leukemia (ALL) from a medical center in northern India, sepsis (53.3%) and bleeding (15.7%)
were the most common causes of mortality in the 128 deaths that were recorded (24% death
rate)38. When you contrast this death rate to the 2.6% death rate reported from an analysis of the
causes of death, other than resistant disease or relapse, in 875 children with ALL treated on 3
different Dutch Childhood Oncology Group ALL protocols, the difference in death rates is
astonishing. Survival rates in childhood ALL in developing countries with limited resources are
inferior because of infection-related toxic deaths, a higher incidence of relapse, default of
therapy, and loss to follow-up. The main demographic we want our device to serve is children in
developing countries, because as noted above, survival rates in childhood ALL in developing
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countries is lower than in developed countries because of the lack of resources. Our device will
be readily available to these countries because it will be easy and cheap to manufacture, as well
as user friendly, eliminating the need for highly trained staff to perform other diagnostic tests
such as flow cytometry or FACS to observe neutrophil CD64 expression. Additionally, our
device integrates CTC and CTC cluster capture to provide additional prognostic information
about the patient’s cancer status. While our main target demographic is children in developing
countries, our device will also be available to any pediatric patient with blood-based cancer.
Ethical/Health and Safety
As with any prognostic medical device, if an incorrect result is given, this kind of
information could place a heavy burden on the pediatric patient’s mental health, as well as
the child’s family members. Since our main demographic is children, who are not
autonomous and need a legal guardian to make decisions for them, huge responsibility is
placed on the legal guardian to decide if they think it is appropriate to run the prognostic
test.

Chapter 8: Summary and Conclusion
Our work has resulted in the design of a microfluidic device which can process 7.5 mL of
a patient's blood and analyze it for the assessment of leukemia progression, as well as common
leukemia complications, such as metastasis (leukemic or solid-body tumor) and sepsis. Our
device does this by isolating circulating tumor cells and circulating tumor cell clusters for
solid-body tumor metastasis diagnosis, quantifying mRNA levels for sepsis diagnosis, platelet
count for severe sepsis diagnosis, and WBC levels for leukemia progression and lymphoma
metastasis diagnosis.
Our device completes these tasks in three distinct and continuous microfluidic stages.
The first stage utilizes a staggered pillar design to isolate circulating tumor cell clusters for
metastasis assessment and future analysis. The next stage utilizes a labyrinth design to separate
smaller CTCCs, individual CTCs, and blood components for further metastatic assessment. The
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designs for these stages were found in our literature review and then edited in order to achieve
the function we desired in our microfluidic device. The third stage of the microfluidic system is
of our own design and utilizes components commonly found in qPCR experiments. In addition,
the full processing of blood will be completed in less than two hours which is significantly
shorter than modern tests for these diseases. Once the test has completed, the data will include
CTC and CTCC counts in addition to CD64 mRNA quantification, platelet count, and WBC
count to compare against established baselines and pre-set trigger thresholds based on the
various complications the patient might be facing. This data can be used to assess the severity
and presence of leukemia, lymphoma, cancer metastasis, and sepsis.
We designed our device to overcome several shortcomings of previous technologies, such
as a misdiagnosis risk and testing time. Given that both sepsis and leukemia present with high
white blood cell count, it is very important to have a proper diagnostic distinction between the
diseases for proper treatment. Our device allows for facilitated distinction between leukemia and
sepsis because it allows for CD64 quantification, which is unique to sepsis, as opposed to the
standard WBC test. Additionally, the average time of non-emergency complete blood tests is 4.5
hours, which is much too long for an effective test for sepsis. The death rate of sepsis increases
by 7.8% every hour which means that the test must be completed quickly so that treatment can
begin. Our device not only prevents the common misdiagnosis of sepsis but also provides the
quantification of a biomarker which is indicative of sepsis severity in half the time of a normal
blood test.
Our project unfortunately had several limitations because our team was unable to
physically create and test our device as a result of COVID-19. This and several other unexpected
problems forced us to redesign our project several times and limited the amount of time we had
to work on the project. In addition, we were limited by the availability of data that was
applicable to our work. Because we could not test our device, the data we utilized for our project
had to be taken from outside sources. This was problematic because there are not a significant
amount of studies done that result in data similar to the data we would be achieving from our
device. We were instead forced to utilize data from studies and fit them to our work as best as
possible.
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We believe that this project will contribute to the medical community by providing a
faster, smaller, and simpler device to test for cancer complications. We believe that we are also
contributing to the community of Santa Clara University by helping those less fortunate by
creating a device primarily for the benefit of a pediatric demographic, that also can be used by
those in developing countries. Finally, we are contributing to our group members by allowing us
to have an opportunity to learn new things in the world of medical device bioengineering, as well
as prevent or reduce severity of medical complications that we may have a personal connection
with.
If a future group were to pick up our project we would recommend that they work on
increasing the efficiency of the device. This includes reducing the total run time of the device
and potentially increasing the quality of data received. In addition, we recommend utilizing some
sort of electric field within the reservoir chamber to focus the bound mRNA at the top resulting
in more accurate data for sepsis assessment. The main focus of future work, however, should be
actually building and testing the device, as well as writing the necessary programming functions
for automation of the system. This is essential because all of our work is hypothetical until the
device is actually built and tested, and there could be unforeseen issues with the design that
would only become known during a practical test.
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APPENDIX
A.1 Additional Information: Electrode Cell Counter

Figure A.1 Electrode Cell Counter with a top-down view pictured in A, and a side view
pictured in C. The Section titled B shows a picture of the electrode cell counter from the side
with the current represented in white. Adapted from reference A1.

Figure A.5 represents an electrode cell counter which utilizes disruptions of current in
order to count cells as they pass between electrodes. This mechanism of cell measurement is
known as the coulter principle. Between the electrodes, there is a path of current which gets
disrupted when cells pass through it. The disruptions in current are dependent on the size of the
cells which pass between the electrodes allowing for cell quantity and size estimation. The
relative disruptions in current are analyzed through a neural network in order to create these
estimations. This allows for distinguishability between different cell types and quantification of
clustered cells as they pass through the system.

A.2 Additional Information: CTCC Separator Stage 2
The second phase of the cluster separation section of the system utilizes deterministic
lateral displacement in order to separate small clusters of CTCs from single CTCs. The process
begins as the small tumor clusters and single CTCs flow from the first stage of the chip. The
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DLD of this stage works similarly to the first stage of the cluster separation process, however,
the pillars are shaped differently and have different gap sizing. The clusters and single CTCs
enter at the top of the chip and flow downwards through the rows of displaced pillars. Single
CTCs are easily able to weave in between the pillars, the small clusters, however, do not do this.
The pillars are asymmetrically shaped with a circular indent on the right side. This indent alters
the flow of the buffer and cells as it passes by the pillars forcing the small clusters of CTCs to
rotate as they flow past the pillars. This rotation forces the small clusters to exit the indent and
move downwards at a different angle than the single CTCs. The exiting angle of movement for
the small clusters has them move straight downwards rather than horizontally towards the
entrance point as the single CTCs do. The cluster then encounters another pillar which is slightly
lateral to the previous pillar and the process is repeated. Due to the small horizontal displacement
between the pillars, the small clusters end up moving horizontally while the single CTCs only
move vertically. At the bottom of the chip, the individual CTCs are collected directly below the
entry point while the small CTC clusters are collected from an outlet lateral to the entry point.
After stage 2 of cluster separation, single CTCs and other naturally found cells within the blood
move onto the Labyrinth in order to separate the CTCs from the other naturally found cells in the
blood sample.

Figure A.2: Cartoon sketch of Stage 2 of the CTCC separator showing the DLD
process. Adapted from Ref A2.
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A.3 Requirement List
● Less than 2 hour testing time
● Testing for sepsis, CTCs, and CTCCs, and assessing leukemia and lymphoma
● $1500 budget
● 2 month time limit

A.4 Sketches/Alternate Designs

Figure A.3: The original AutoCAD for the Labyrinth section based on the respective
reference literature.
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Figure A.4: The original AutoCAD for the later discarded CD64 antibody-based sepsis
analyzer. Red layer symbolizes control layer. Green layer symbolizes flow layer.

Figure A.5: The original AutoCAD for the 2-phase CTCC separator based on the respective
reference literature.
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Figure A.6: First draft of the combined system with the 2-phase CTCC separator, Labyrinth
design, and CD64 antibody-based sepsis analyzer.

Figure A.7: New design for sepsis analysis based on fluorescent CD64 analysis using rotary
mixer and lysing/quenching maze.

47

Figure A.8: Second draft of the combined system with the 2-phase CTCC separator, Labyrinth
design, and new design for sepsis analysis based on fluorescent CD64 analysis using rotary
mixer and lysing/quenching maze.
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Figure A.9: Third draft of the combined system with the first phase of the CTCC separator,
Labyrinth design, and sepsis analyzer based on fluorescent CD64 analysis using rotary mixer
and lysing/quenching maze. Resized valves and large imaging chamber added.
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Figure A.10: Fourth and final draft of the combined system with the first phase of the CTCC
separator, Labyrinth design, and sepsis analyzer based on fluorescent CD64 analysis using
rotary mixer and lysing/quenching maze. Mixing and imaging chambers resized and pillars
added to increase structural integrity. Color added to differentiate layers.

A.5 Decision Rationale
As seen above, we went through several different versions of some of the components, as
well as several versions of the overall design. We started with AutoCAD designs largely based
on the reference figures, but quickly adapted them based upon some aspects that needed to be
changed. The main and largest change was from the CD64 antibody-based sepsis analyzer seen
in Figures A.4 and A.6 to the new device based on mRNA seen in Figures A.7 through A.10.
We decided to create our own device for sepsis assessment rather than utilizing designs
from our literature review because these designs lacked important characteristics which we
desired for our design. One design which we initially focused on, utilized antibodies to capture
and enumerate CD64 expressing WBC’s for sepsis diagnosis. The problems with this design, and
other designs similar to it, is that they are overly complicated and take a significant amount of
time to complete the test. The operating time is incredibly important for sepsis diagnosis because
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the disease progresses rapidly, so the diagnosis must be very quick. When creating our sepsis
diagnosis design, we focused on reducing the time of operation and complexity of our device in
order to get quick results and allow facilitated integration with other components in our system.
The next few modifications to the design came from removing the second phase of the
cluster separator, resizing the mixing and imaging chambers for sepsis analysis, resizing the
valves, and adding a new layer. The removal of the second phase of the cluster separator was
largely based around reducing the time, given that the original CTCC separation time was 7.53
hours, and removing phase 1 reduced that time by 6.49 hours. Additionally, the main point of the
second phase, to remove small CTCCs, can be accomplished by the Labyrinth. This also rescues
complexity of the design.
The resizing of the imaging and icing chambers was because we initially had the idea to
have only one layer of WBC components for imaging, but we soon realized that this forced the
imaging chamber to be too large. This is also why we added pillars to add structural integrity,
since even the smaller size was still not stable and would likely be prone to collapse. We also
resized all of the valves to a single size for simplicity and better accessibility. The blue layer was
added because the larger height of the Labyrinth component and mixing chamber does not allow
for them to be printed within the same layer as Flow or Control.
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A.6 Calculations

Figure A.11: First version of time test, calculated by design section. Time is too long,
requiring design changes
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Figure A.12: Blood component calculations, based on only WBCs needing to be analyzed for
sepsis. Findings show significant time reduction for sepsis analyzer
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Figure A.13: Second version of time test, calculated by design section and based on blood
component calculations. Time is better, but still too long, requiring further design changes

54

Figure A.14: Time calculation for CTCC separator based on length. Removing Stage 2
appears to be a necessary time-saving measure eliminated by redundancy from the Labyrinth
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Figure A.15: Third version of time test, calculated by design section and based on CTCC
length calculation. Time is within 2 hours, which meets our goal
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Figure A.16: Calculation of size of imaging chamber needed for 1-layer imaging. Size reduced
to allow for 2-3 layers, reducing size needed
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A.7 Academic Timeline for Microfluidic Liquid Biopsy for Cancer Prognosis
Spring Quarter 2020
Week 1

Literature Review and Research

Week 2

Literature Review and Research

Week 3

Literature Review and Research

Week 4

Initial Idea Proposal and Design

Week 5

Initial AutoCAD Design and Additional Research

Week 6

Sepsis Assessment Research and Section Addition

Week 7

Secondary AutoCAD Design and Additional Research

Week 8

Final Design Creation and Restructuring

Week 9

Senior Design Presentation

Week 10

Final Thesis Completion

A.8 Literature Review
1) Sarioglu, A., Aceto, N., Kojic, N. et al. A microfluidic device for label-free, physical capture
of circulating tumor cell clusters. Nat Methods 12, 685–691 (2015).
https://doi.org/10.1038/nmeth.3404

This study utilizes a “Cluster Chip” design to isolate circulating tumor cell clusters from
unprocessed blood with a high capture efficiency for breast and prostate cancers. The design
captured 99% of CTCCs that were composed of 4+ cells, 70% of 3 cell CTCCs, and 40% of 2
cell CTCCs. This chip flowed the whole blood sample at a rate of 2.5ml/h utilizing many
different raised triangular pillars with integral separation points where the vertices of the
triangles meet. This small space between the vertices allows normal blood cells and single
circulating tumor cells through but holds CTCCs. Even if the CTCCs are oligoclonal, the
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bifurcating edge of the triangular pillar provides a dynamic force balance utilizing cell-cell
connecting forces to hold the CTCCs.
The cluster chip method outperforms membrane-based separation methods for CTCC
separation. Pore based filtration tends to break up or lose CTCCs during wash steps. Therefore,
utilizing the cluster chip methods results in a higher capture efficiency than membrane-based
separation methods. In addition, this method outperforms antibody-based microfluidics for
CTCC capture by 50-400%.

2) Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., Yu,
M., Pely, A., Engstrom, A., Zhu, H., Brannigan, B. W., Kapur, R., Stott, S. L., Shioda, T.,
Ramaswamy, S., Ting, D. T., Lin, C. P., Toner, M., Haber, D. A., & Maheswaran, S. (2014).
Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell,
158(5), 1110–1122. https://doi.org/10.1016/j.cell.2014.07.013Metastasis

This article describes the CTCC formation process in detail with a focus on intracellular
connection. The study utilizes mouse models with tagged mammary tumors to demonstrate that
CTCCs form from oligoclonal tumor cell groupings rather than intravascular aggregation. The
intracellular CTCC connection relies on a protein known as plakoglobin and the abrogation of
this protein prevents CTCC formation.
This study demonstrates that CTCCs have a 23-50 fold increased metastatic potential,
that CTCCs represent 2-5% of total CTCs. The study also shows that CTCCs have better
vascular integrity and longevity, surviving roughly three times longer than CTCs when in
circulation.
3) Au, S.H., Edd, J., Stoddard, A.E. et al. Microfluidic Isolation of Circulating Tumor Cell
Clusters by Size and Asymmetry. Sci Rep 7, 2433 (2017).
https://doi.org/10.1038/s41598-017-01150-3
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This study utilizes a two-stage continuous microfluid chip to separate CTCCs from a
whole blood sample using deterministic lateral displacement capitalizing on size and asymmetry.
The first stage of the chip utilizes rows of slightly offset pillars which allow small clusters and
cells to weave through the pillars while forcing large clusters towards the right side of the chip
through deterministic lateral displacement where they can be captured. The second stage of the
chip uses rows of slightly offset asymmetric pillars with a cleft on their right side to separate
smaller CTCCs from single CTCs and blood cells. This second stage utilizes a low ceiling to
force small CTCCs to flatten and rotate through the pillars due to their asymmetry. This forces
the small CTCCs to be unable to weave through the pillars and instead move horizontally
through deterministic lateral displacement to the right side where they are collected. The single
cells and whole blood are able to weave around the pillars and become separated from small
CTCCs.
Large CTCCs were designated as having 8+ cells per cluster, and small CTCCs were
designated as having 2-8 cells per cluster. This pillar microfluidic design had a flow rate of
.5ml/h and resulted in a 98.7% capture efficiency for large CTCCs and 65.5% capture efficiency
for small CTCCs. This study had similar, but slightly lower, whole blood CTCC capture
efficiencies when compared to the Cluster Chip design (Source 1).
4) Chou, W.-P., Chiu, T.-K., & Chao, A.-C. (2018). Optically-induced-dielectrophoresis
(ODEP)-based cell manipulation in a microfluidic system for high-purity isolation of integral
circulating tumor cell (CTC) clusters based on their size characteristics. Sensor and Actuators B:
Chemical, 258, 1161–1173. Retrieved from
https://www.sciencedirect.com/science/article/abs/pii/S0925400517323298?casa_token=DEUa4l
xqwb8AAAAA:D1_4zxuRwc3peWX9AL1Jf9rIo5OCzu0A-ZquYeF0_MB-MUkTTwzN3XH2y
ZiHVmFQu0lwW3utKg

This article utilizes optically induced dielectrophoresis (ODEP) based cell manipulation
to separate CTCs and CTCCs based on their size characteristics. The chip utilizes an AC current
to create an electric field which becomes dynamic based on how the light source hits the
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photoconductive layer. This dynamic electric field is utilized to separate cells and microparticles
based on the size of relative cells, clusters, and particles. This ODEP separation process involves
two steps. In the first step, a dynamic square light image array separates CTCCs and in the
second step, another ODEP based cell manipulation to refine the purity of the harvested CTCCs.
This separation process had a cell purity rate of 91.5% and a recovery rate of 70.5%.
This optically induced dielectrophoresis separation mechanism had a significantly lower
CTCC separation efficiency than simple size and shape based microfluidic separation
mechanisms analyzed previously such as the cluster chip and the pillar chip.

5) Xu, L., Mao, X., Imrali, A., Syed, F., Mutsvangwa, K., Berney, D., Cathcart, P., Hines, J.,
Shamash, J., & Lu, Y. J. (2015). Optimization and Evaluation of a Novel Size Based Circulating
Tumor Cell Isolation System. PloS one, 10(9), e0138032.
https://doi.org/10.1371/journal.pone.0138032

This article performs a review of the Parotix CTC and CTCC separation system. This
system utilizes extracellular ligands found on CTCs and CTCCs to separate them from whole
blood samples. Problems with the study include the inconsistency of available ligands on CTCs
for binding. The study utilizes an immunofluorescence based system for quantification of
captured cells and achieved a separation of roughly 60% depending on cell type and buffer use.
This article compared the Parotix separation system to the Cell Search and IsoFlux
systems and achieved a similar separation efficiency to them. In addition, this article had a focus
on CTC capture however it also captured CTCCs as well. The separation efficiencies of the
optimized Partotix system are roughly 30% lower than the Cluster Chip and Pillar based CTCC
separation mechanisms.
6) Mario Giuliano, Anum Shaikh, Hin Ching Lo, Grazia Arpino, Sabino De Placido, Xiang H.
Zhang, Massimo Cristofanilli, Rachel Schiff and Meghana V. Trivedi (2018). Perspective on
Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. Cancer Res February 15
2018 (78) (4) 845-852; DOI: 10.1158/0008-5472.CAN-17-2748
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This article includes a thorough description of the mechanisms involved in CTCC
metastasis and highlights the importance of research in this area. CTCCs not only have a roughly
40-50 times higher chance of resulting in successful metastasis but they also may result in
communication between tumor sites and explain how certain cancers can survive extensive
treatment pressures. In addition, the clusters have a higher rate of survival within circulation,
which is likely due to adhesive cooperation of the cells within the cluster to counteract shear
forces, environmental and oxidative stress, and immune assaults.
This article also highlights the benefits of using microfluidic devices for CTCC
separation and which microfluidic designs are most effective for cluster separation. Microfluidic
devices are effective for cluster separation because they are able to process whole blood without
the need for RBC removal and because they can separate CTCCs without killing them. The
article states that spiral systems, the cluster-chip platform, and deterministic lateral displacement
are the most effective microfluidic designs for cluster separation.

7) Vasudha Murlidhar, Rishindra M. Reddy, Shamileh Fouladdel, Lili Zhao, Martin K. Ishikawa,
Svetlana Grabauskiene, Zhuo Zhang, Jules Lin, Andrew C. Chang, Philip Carrott, William R.
Lynch, Mark B. Orringer, Chandan Kumar-Sinha, Nallasivam Palanisamy, David G. Beer, Max
S. Wicha, Nithya Ramnath, Ebrahim Azizi and Sunitha Nagrath (2017). Poor Prognosis
Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers Cancer Res
September 15 2017 (77) (18) 5194-5206; DOI: 10.1158/0008-5472.CAN-16-2072
This article assesses the efficacy of prognosis based on the detection of circulating tumor
cells and their clusters from whole blood in different locations within the body. The blood was
obtained during tumor removal surgeries from pulmonary veins and peripheral veins. The study
found that there was a higher concentration of CTCs and CTCCs in pulmonary veins than
peripheral veins and this is alarming due to the potential mobility of the location.
In addition this article found that 50% of the tested patients had circulating tumor cell
clusters in their blood. This consistency is much higher than estimates based on the rarity of
these clusters. This high consistency is also very problematic due to the significantly higher
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metastatic potential associated with clusters. The study also found that the presence of circulating
tumor cell clusters was associated with poor prognosis. This is likely due to the high metastatic
potential associated with these cell clusters.
8) Yoon, Y., Lee, J., Ra, M., Gwon, H., & Lee, S. (2019). Continuous Separation of Circulating
Tumor Cells from Whole Blood Using a Slanted Weir Microfluidic Device. MDPI, 11( 2). doi:
https://doi.org/10.3390/cancers11020200

Design Specifications:
● 4.5 × 4.5 cm2 surface oxidized silicon chip.
● Main Channel is 500um
● Double-layer photolithography was used to pattern the slanted weir integrated
microfluidic channel
● The first layer was spin-coated with a SU-8 2050 (Microchem, Westborough, MA, USA)
photoresist, which was 23 μm thick, and the weir structure was patterned.
● The second layer, which defines the weir gap, was spin-coated with the SU-8 2007
(Microchem) photoresist, which was 7 μm thick.

Efficiency:
● Dependent on Weir angle, multiple were tested.
● The weir angles that produced ΔPx/ ΔPy > 1 (0.5° and 0.8°) resulted in very high
separation efficiencies, showing values of ~95% efficiency.

Flow Rate:
● ΔPy s hould be 50 PA, therefore, ΔPx should be slightly higher (50-60PA)
● The sample-to-buffer flow rate ratio must be 1:4 or with a higher portion of the buffer
flow rate.
● The total flow rate was set at 2.5 mL/h for the 0.8° weir and at 3.8 mL/h for the 0.5° weir,
which produced a ΔPy of 50 Pa
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9) Zhou, J., Kulasinghe, A., Bogseth, A. et al. Isolation of circulating tumor cells in
non-small-cell-lung-cancer patients using a multi-flow microfluidic channel. Microsyst Nanoeng
5, 8 (2019). https://doi.org/10.1038/s41378-019-0045-6

Specifications:
● Replicated straight channels (150 μm wide, 50 μm high, and 20 mm long) in PDMS
were bonded to 1″ × 3″ glass slides
● Microchannels were fabricated via standard soft photolithography.
Other inertial migration testing also utilized this channel sizing
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356955/)

Efficiency:
● For cell line H460, the recovery rate is more than 93%

Flow Rate:
● The flow rate ratio is defined as the sample flow rate (Qs) over the buffer flow rate (Qb ).
The total flow rate (Qt = Qs + Qb) was fixed at 300 µL/min, equivalent to Re = 50.
10) Mustjoki S, Sidenius N, Sier CF, et al. Soluble urokinase receptor levels correlate with
number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during
chemotherapy. Cancer Res. 2000;60(24):7126-7132.
This article focuses on plasminogen activation and its role in metastasis specifically for
acute myeloid leukemia. The study focuses on urokinase(uPA) and its receptor (uPAR) and
shows that they have a significant role in the cell migration and tumor cell invasion aspects of
metastasis. Data has shown that the upregulation of uPAR correlates with a poor response to
chemotherapy and that for leukemia specifically, high levels of plasma soluble uPAR (suPAR)
also correlates with a poor response to chemotherapy.
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This study measured levels of uPAR in cells, plasma, and urine in patients with acute
leukemia throughout a 56-day time frame. The results were that, as levels of CTCs decreased
with chemotherapy, levels of suPAR decreased as well. However, bone marrow aspirations of
patients with acute leukemia demonstrated excessive levels of suPAR. These results suggest that
CTCs secrete excessive amounts of suPAR likely as a means to escape the danger of circulation
and migrate into other parts of the body creating secondary tumor sites.
11) Kulasinghe, A., Zhou, J., Kenny, L., Papautsky, I., & Punyadeera, C. (2019). Capture of
Circulating Tumour Cell Clusters Using Straight Microfluidic Chips. Cancers, 11(1), 89.
https://doi.org/10.3390/cancers11010089

In this study, the authors investigated the presence of CTCs and circulating tumor
microemboli (CTMs) in head and neck cancers using a novel straight microfluidic chip
technology that exploits size-based differences between CTCs and haematopoietic cells. The
device has a channel width of 150 µm and height of 50 µm, with two inputs and two outputs.
Buffer (PBS) is introduced at the inner inlet and sample at the outer inlet, which forms two
sample flows sandwiching a buffer flow in the middle of the microchannel. Cells migrate
laterally away from the sample streams into the clean buffer stream due to inertial forces. The
channel length can be precisely controlled to select larger CTCs and clusters, separating them
from WBCs, because inertial migration is strongly dependent on size. CTCs and clusters are
collected in the inner outlet and all other waste cells exit the channel through the outer outlet.
Operating at a flow rate of 100 and 200 µL/min for the sample and PBS solution respectively,
the device was tested with several spike-in and recovery experiments using three HNC cell lines.
The percentage recovery for cell counts between 50–500 cells ranged from 70–96%, and
40–80% for spike-in experiments of 10 cells. The researchers also tested the device on head and
neck cancer (HNC) patient blood samples, and found that single CTCs and CTC clusters were
present at all stages of the disease.
This device overcomes the limitations of current CTC enrichment technologies that use
surface marker expression (positive selection), or the removal of non-cancer cells (negative
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selection) to enrich cancer cells. These positive and negative selection methods are poor in
discriminating between individual CTCs and CTC clusters. However, a limitation of this
microfluidic chip is that small CTCs, which have a comparable size to WBCs, are unlikely to be
captured using size based exclusion technologies.
12) Lin et al. (2017). High-Throughput Microfluidic Labyrinth for the Label-free Isolation of
Circulating Tumor Cells. Cell Systems 5, 295–304 September 27, 2017
http://dx.doi.org/10.1016/j.cels.2017.08.012

The authors of this study designed a device inspired by the Labyrinth in Greek
mythology, which was an elaborate structure with numerous turns and corners built to hold the
Minotaur. The “Labyrinth” is a label-free microfluidic device that isolates circulating tumor cells
(CTCs) using the combination of long loops and sharp corners to focus both CTCs and white
blood cells (WBCs). The total channel length of the Labyrinth is 637 mm, the channel is 500 µm
in width and 100 µm in height, and it consists of 11 loops and 56 corners.The loops, which have
a small curvature ratio, provide enough length of channel to achieve total focusing of cells and to
have the proper curvature for the separation of CTCs and blood cells. The 56 sharp right-angle
corners, which have high curvature ratio, further enhance the focusing of smaller cells. The
channel expands from a width of 500 µm to 1000 µm before diverting into four separate outlets
to collect WBCs, CTCs, RBCs and other blood components. The percent recovery in outlet 2
during one of the control experiments was 91% for WBCs, 92% for PANC-1 cells, 90% for
H1650 cells, and 91% for MCF-7 cells to list a few.
The reason the authors wanted to develop a label-free isolation method is because many
microfluidic devices rely on positive or negative selection to isolate CTCs, such as the
immune-affinity capture method that utilizes antibodies to target molecules, such as the epithelial
cell adhesion molecule (EpCAM), which are expressed exclusively on tumor cells. The
drawback with these methods however, is that not all CTCs express EpCAM, and downstream
single cell-analysis of captured CTCs can be challenging due to complex protocols that may
interfere with RNA stability during the release step of CTCs from devices.
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13) Wan, S., Kim, T.H., Smith, K.J. et al. New Labyrinth Microfluidic Device Detects
Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor
Microemboli in Hepatocellular Carcinoma. Sci Rep 9, 18575 (2019).
https://doi.org/10.1038/s41598-019-54960-y

The authors of this study developed and optimized a novel Labyrinth microfluidic device
to efficiently isolate CTCs from peripheral blood of Hepatocellular Carcinoma (HCC) patients.
They made modifications to the original Labyrinth and increased the height of the channel to 110
µm. This modification increased the Dean force effect, allowing the cells to equilibrate at similar
focusing positions at lower flow velocities, which reduced the overall shear stress acting on the
CTCs during separation. The Labyrinth device has an inlet to inject the sample, and four outlets.
Outlet 1 collects WBCs, outlet 2 collects CTCs, and outlets 3 and 4 were included to reduce the
sample fluid volume after cell separation and collection. Spike-in experiments to determine the
recovery rate of CTCs in outlet 2, at the determined optimal flow rate of 2000 µL/min, revealed a
recovery rate of 91.17% and 95.69% for Hep 3B and Hep G2 cells respectively after considering
only the cells with a size above the cut-off cell diameter entering the outlet. The WBC depletion
rate at this optimal flow rate was determined to be 97.66 ± 0.53%. After optimizing the flow
rate of the Labyrinth with spike-in experiments, the researchers tested the device with peripheral
blood from HCC patients, and identified CTCs in 88.1% of the patients over different tumor
stages. Interestingly, they also found that 55% of the patients had the presence of circulating
tumor microemboli (CTM), sometimes referred to as circulating tumor cell clusters (CTCCs).
14) Kamyabi, N., Huang, J.,Lee, J., et al. A microfluidic device for label-free isolation of tumor
cell clusters from unprocessed blood samples. Biomicrofluidics 13, 044111 (2019)
https://doi.org/10.1063/1.5111888

In this study, the authors wanted to address some of the drawbacks of other devices
designed to isolate CTC clusters. Microfilters have been used to capture clusters, because
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clusters are significantly larger than single cells and can be arrested at the pores of the filter. The
major drawback of this method is that you are prone to lose some of the clusters due to their
deformability and subsequent transit through the pores. Another device, called the Cluster-Chip,
contains a parallelized array of equilateral triangle shaped pillars. Clusters are wedged within a
three-pillar unit, arrested due to a dynamic force balance between cell-cell adhesion strength,
fluid drag forces, wall friction, and reactionary forces from the pillars. The potential drawback of
this device is the possibility of cluster damage and inefficient capture because of the fact that the
triangular pillars have sharp edges and the clusters interact with multiple three-pillar units.
The authors developed a new microfluidic device for isolating CTC clusters
(“Microfluidic Isolation of CTC Clusters” or MICC platform) from unprocessed blood samples.
The MICC platform is equipped with approximately 10,000 trap chambers that isolate tumor cell
clusters based on their large sizes and dynamic force against a pillar obstacle in the trap chamber,
similar to the Cluster-Chip. One of the factors that makes CTC cluster separation so difficult is
that the shear forces in typical microfluidic devices are strong enough to separate the clustered
CTCs. In the trap chamber of the MICC platform, the dynamic forces holding a cluster together
are stronger than shear forces, so cluster separation is not an issue. Under optimal flow
conditions and using blood samples spiked with different concentrations of clusters, the MICC
platform performed with a capture efficiency of 66%–87% and release efficiency of 76%–90%.
15) Gou, Y., Zhang, S., Sun, C., Wang, P., You, Z., Yalikun, Y., . . . Ren, D. (2019). Sheathless
Inertial Focusing Chip Combining a Spiral Channel with Periodic Expansion Structures for
Efficient and Stable Particle Sorting. Analytical Chemistry, 92(2), 1833-1841.
doi:10.1021/acs.analchem

In this study, the authors improve upon the typical spiral channel microfluidic device by
incorporating periodic expansion structures for the sheathless separation of particles with
different sizes. The inertial lift force, which these microfluidic devices rely on to separate
particles, is difficult to quantitatively analyze because of the uncertainties of its magnitude and
direction. This means that the equilibrium position of the particles varies along the migration
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process, thus inducing the instabilities of particle separation. In the spiral channel microfluidic
device with periodic expansion structures, a stable vortex-induced lift force arises from the
periodic expansion. The stable vortex-induced lift force along with the Dean drag force
significantly enhance the focusing process, with experimental results showing that over 99% of
target particles could be isolated with the high target sample purity of 86.12%.
16) Icardi, M., Erickson, Y., Kilborn, S., Stewart, B., Grief, B., & Scharnweber, G. (2009).
CD64 index provides simple and predictive testing for detection and monitoring of sepsis and
bacterial infection in hospital patients. Journal of clinical microbiology, 47(12), 3914–3919.
https://doi.org/10.1128/JCM.00628-09

In this article, the authors conduct a study to confirm and extend the previous literature
that provides evidence that granulocyte CD64 expression is predictive of sepsis and bacterial
infection. They measured CD64 expression by granulocytes of 113 patient blood samples (4
were determined ineligible) using a Leuko64 kit (Trillium Diagnostics, ME) and a BD
FACSCalibur running Quanticalc software (Verity Software House, ME). 24 blood samples from
healthy individuals and 20 blood samples from patients who had undergone uncomplicated
surgeries were used for controls. In each blood sample, lymphocytes were used as an internal
negative control and monocytes as an internal positive control. After performing
fluorescence-activated cell sorting (FACS), they calculated the CD64 index using the ratio of the
mean fluorescent intensity of the cell populations (lymphocytes and monocytes) to that of the
beads. In order for the internal controls to be considered valid, the lymphocytes should have a
CD64 index of <1 and monocytes an index of >3. After obtaining the CD64 indices of the blood
samples and performing blood cultures, the researchers categorized the patients into four groups:
no infection, clinical infection, culture-proven infection, and blood culture-proven infection.
After performing statistical analysis and constructing receiver operating characteristic (ROC)
curves for the CD64 index and WBC counts, the point of maximum test efficiency, sensitivity,
specificity, likelihood ratios, and positive and negative predictive values were calculated (point
of maximal efficiency = 1.19 (P value = 0.000019), sensitivity = 94.6%, specificity = 88.7%,
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positive likelihood ratio = 8.36, negative likelihood ratio = 0.06, positive predictive value =
89.8%, negative predictive value = 94%). Comparing the CD64 indices to the blood culture
results, it was determined that an index >1.19 detected all of the culture-positive patients and an
index of ≤1.19 was 100% predictive of a “no-growth” blood culture.
The total turnaround time for this test is approximately 45 min, which is a huge
improvement compared to the turnaround time of the gold standard for diagnosing sepsis, blood
culture. It takes up to two days to obtain results from blood culture, and sepsis patients can
experience severe complications within that time frame. This study validates our reason and
motivation for selecting CD64 as a neutrophil biomarker in the diagnosis of sepsis associated
with leukemia. We expect our microfluidic device to be more user friendly than FACS systems,
and as a result will be able to be used by medical staff to constantly and consistently monitor
patients suspected of having sepsis.
17) Yin, W. P., Li, J. B., Zheng, X. F., An, L., Shao, H., & Li, C. S. (2020). Effect of neutrophil
CD64 for diagnosing sepsis in emergency department. World journal of emergency medicine,
11(2), 79–86. https://doi.org/10.5847/wjem.j.1920-8642.2020.02.003

The authors of this study investigated the diagnostic and prognostic value of neutrophil
CD64 (nCD64) as a novel biomarker in sepsis patients, and compared it to other indicators of
bacterial infection such as elevated levels of C-reactive protein (CRP), procalcitonin (PCT), and
white blood cells (WBC). WBC count, PCT levels, and CRP levels were measured from 151
adult patients diagnosed with sepsis and 20 healthy controls. Samples of blood, urine, sputum, or
bronchoalveolar lavage fluid were collected to perform bacteriological culture and confirm
bacterial infection. Individual Sequential Organ Failure Assessment (SOFA) scores were
calculated and patients were followed up for up to 28 days. nCD64 levels were determined by
flow cytometry using residual blood from routine blood samples. After performing statistical
analysis, it was determined that nCD64 expression was higher in the sepsis group with confirmed
infection than in the control group. The receiver operating characteristic (ROC) curve of nCD64
was higher than those of SOFA score, CRP, PCT, and WBC for diagnosing infection. However,
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the area under the curve (AUC) of nCD64 was slightly lower than the AUC of the SOFA score,
which means that the SOFA score is better for predicting 28-day mortality in sepsis. That is why
the authors concluded that combining both parameters, nCD64 expression and the SOFA score,
was the best approach to diagnose sepsis early and improve patient outcomes.
This study also validates our reason and motivation for selecting CD64 as a neutrophil
biomarker in the diagnosis of sepsis associated with leukemia, as it has been shown to
outperform CRP, PCT, and WBC levels as indicators of sepsis. Even though the SOFA score
was slightly better at predicting 28-day mortality in sepsis patients, the expression of nCD64 is in
our opinion, the fastest and easiest parameter to measure in diagnosing sepsis because a SOFA
score is merely a mortality prediction score that is based on the degree of dysfunction of six
organ systems.
18) Marwaha, R. K., Kulkarni, K. P., Bansal, D., & Trehan, A. (2010). Pattern of Mortality in
Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 32(5),
366-369. doi:10.1097/mph.0b013e3181e0d036

In this study, the authors performed a retrospective analysis of 532 patient case records of
children with acute lymphoblastic leukemia (ALL) in the period between January 1990 and
December 2006. After analyzing the case records, it was determined that sepsis (53.3%) and
bleeding (15.7%) were the most common causes of mortality in the 128 deaths that were
recorded (24% death rate). When you contrast this death rate to the 2.6% death rate reported
from an analysis of the causes of death, other than resistant disease or relapse, in 875 children
with ALL treated on 3 different Dutch Childhood Oncology Group ALL protocols, the difference
in death rates is astonishing. Survival rates in childhood ALL in developing countries with
limited resources are inferior because of infection-related toxic deaths, a higher incidence of
relapse, default of therapy, and loss to follow-up.
The main demographic we want our device to serve is children in developing countries,
because as noted above, survival rates in childhood ALL in developing countries is lower than in
developed countries because of the lack of resources. Our device will be readily available to

71

these countries because it will be easy and cheap to manufacture, as well as user friendly,
eliminating the need for highly trained staff to perform other diagnostic tests such as flow
cytometry or FACS to observe neutrophil CD64 expression. Additionally, our device integrates
CTC and CTC cluster capture to provide additional diagnostic and prognostic information about
the patient’s cancer status.
19) Sin, A., Murthy, S. K., Revzin, A., Tompkins, R. G., & Toner, M. (2005). Enrichment using
antibody-coated microfluidic chambers in shear flow: Model mixtures of human lymphocytes.
Biotechnology and Bioengineering, 91(7), 816-826. doi:10.1002/bit.20556

The authors of this study were able to demonstrate the possibility of using dynamic cell
attachment to antibody-coated microfluidic chambers in shear flow to enrich mixtures of
MOLT-3 and Raji cells, both human lymphocyte cell lines. MOLT-3 cells are human immature
T-lymphoblasts that express CD5 but not CD19, and Raji cells are human mature B-lymphocytes
that express CD19 but not CD5. After incubating the cells and diluting them to a concentration
of approximately 1 x 106 cells/mL, cell mixtures containing both cell lines were created. Shear
stresses ranging between 0.75 and 1.0 dyn/cm2 provided most efficient capture of cells based on
affinity to antibody coated surfaces while reducing or eliminating undesired binding by the cell
of interest. They were also able to verify that the dynamic cell adhesion of Raji and MOLT-3
follows a pseudo-first order kinetic model. They were able to obtain 100% pure MOLT-3 cells
with an anti-CD19 coated device with approximately 2.6 min residence time, and around 75%
Raji cells with an anti-CD5 coated device with approximately 3 min residence time. For both
experimental tests, an almost 50-50 heterogenous cell mixture of MOLT-3 and Raji cells was
used.
Other techniques currently used to isolate phenotypically-pure cell populations from
heterogeneous cell mixtures include fluorescent activated cell sorting (FACS) and magnetic
activated cell sorting (MACS). However, the drawback of these techniques is that they require
pre-incubation with antibodies, which extends the processing time to at least 15-60 min. Our
CD64+ neutrophil test is essentially doing the same as the device in this study, except that we are
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enriching CD64+ neutrophils using an anti-CD64 coated microfluidic device in shear flow. This
study demonstrates that under correct shear stresses, our device is very feasible and realistic.
20) Jackson, J. M., Taylor, J. B., Witek, M. A., Hunsucker, S. A., Waugh, J. P., Fedoriw, Y.,
Shea, T. C., Soper, S. A., & Armistead, P. M. (2016). Microfluidics for the detection of minimal
residual disease in acute myeloid leukemia patients using circulating leukemic cells selected
from blood. The Analyst, 141(2), 640–651. https://doi.org/10.1039/c5an01836f

In this study, the authors developed a microfluidic assay that was able to isolate and
phenotypically identify leukemic cells circulating in a patient’s peripheral blood. They
performed a pilot clinical study where acute myeloid leukemia (AML) patients recovering from
stem cell transplant (SCT) therapy were tracked by isolating CD33, CD34, and CD117
expressing circulating leukemic cells (CLCs) using three sinusoidal microfluidic devices
arranged in a parallel configuration. Each device contains ≥50 parallel microchannels with a
sinusoidal architecture and mAbs covalently attached to the surface of the channels. They were
able to detect minimal residual disease (MRD) 28 days following SCT and the onset of relapse at
day 57, which is a lot better than detection using PCR. PCR from a bone marrow biopsy did not
detect MRD until day 85 of the same patient tested with the microfluidic assay.
While our project doesn’t necessarily focus on CLCs in AML patients, this concept is
something that future students should consider integrating into our device, maybe even replacing
the CTC devices.

21) Tan, J., Ding, Z., Hood, M., & Li, W. (2019). Simulation of circulating tumor cell transport
and adhesion in cell suspensions in microfluidic devices. Biomicrofluidics, 13(064105). doi:
10.1063/1.5129787
This paper focuses more on the modeling of CTC transport and adhesion than a new way
to separate them, but it allows for the principles within to be applicable to both active and
passive separation mechanisms. It also specifically mentions shifted post (columnar) passive
separation designs, noting that the majority of cells only follow streamlines at low
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concentrations. At standard concentrations, the collisions between red blood cells and CTCs or
CTCs amongst each other cause a difference in trajectory from the expected streamline. This
hampers the ability to create an accurate streamline-based model of cell trajectory for accurate
sized-based filtration. This difference in trajectory increased with column size and cell
concentration.
Simulation is also difficult due to the cell deformation affecting the flow and vice versa,
in addition to the vast number of cells that need to be modeled to get an accurate concentration.
This was solved using the lattice Boltzann equation, immersed boundary method, and a
coarse-grained molecular dynamics method to create an accurate computerized computational
simulation model. Adhesion of the CTCs was also tested, finding “2562 [out of 2562] surface
nodes can capture the cell deformation with a reasonable accuracy”.
“Based on the actuation mechanism, these microfluidic devices can be grouped into two
categories: active ones and passive ones. Active microfluidic devices used external assistance
such as magnetic field, electric field, optical forces, and acoustic fields to enrich CTCs. Among
these methods, they either require sophisticated cell preparations, complex microfluidic designs,
or external fields. On the other hand, passive devices utilize the hydrodynamics and physical
properties of CTCs such as size, deformability, and specific binding between receptors expressed
on cell membrane and ligands coated on microfluidic surfaces to separate CTCs from other
cells.”

22) Chen, J., Liu, C.-Y., Wang, X., Sweet, E., Liu, N., Gong, X., & Lin, L. (2020). 3D printed
microfluidic devices for circulating tumor cells (CTCs) isolation. Biosensors and Bioelectronics,
150(111900). doi: 10.1016/j.bios.2019.111900

This paper discusses the best way to 3D print a microfluidic device to capture CTCs from
blood. These devices combined mechanical separation techniques with anti-EpCAM antibodies
for capture and isolation. The paper also discusses the optimal flow rate (1 mL/h) and optimal
channel length (2 cm) for these different designs. These designs were tested with breast, colon,
and prostate cancer, all EpCAM positive, reaching a capture efficiency of around 90%. In
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summary, this paper shows that 3D printed microfluidic devices can be just as effective as those
created from other methods, as well as the details of how best to 3D print a microfluidic device.

●

3D printing technology was used to fabricate a microfluidic device that can increase inner

surface area and manipulate fluid flow.
●

The 3D printed microfluidic device was demonstrated to isolate CTCs from human blood

samples.
●

The capture efficacy using antibody-modified 3D printed microfluidic devices can reach

as high as 90%.
●

The isolation of CTCs from patient blood samples enables both early cancer diagnostics

and treatment progresses.
23) Rostami, P., Kashaninejad, N., Moshksayan, K., Saidi, M. S., Firoozabadi, B., & Nguyen,
N.-T. (2019). Novel approaches in cancer management with circulating tumor cell clusters.
Journal of Science: Advanced Materials and Devices, 4(1), 1–18. doi:
10.1016/j.jsamd.2019.01.006

This paper focuses on new ways to separate circulating tumor cell clusters from a
patient’s bloodstream. While CTC cluster research is a fairly new field, the analysis of them can
offer new insights into how tumors metastasize, which can lead to new ideas on how to cure
cancer as a whole. This paper has a focus on passive separation methods, specifically designed
for the separation of CTC clusters. The paper also thoroughly discusses the role of CTC clusters
in metastasis, their physical and biological characteristics, clinical applications, and current
challenges of CTC clusters.
Interestingly, this paper does not seem to have the main purpose of determining a
patient’s metastasis risk or separating CTC clusters to keep the patient from experiencing
metastasis. Instead, the goal seems to be the separation of CTC clusters to study for research
purposes. The paper discusses a number of different CTC cluster separation techniques in great
detail, usually microfluidic, including antibody, physical property (cell density, size,
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deformability), and photoacoustic. This paper is a great starting point to determine the type of
cluster separation that could be best implemented into our design.
24) Zhang, J., Chen, K., & Fan, Z. H. (2016). Circulating Tumor Cell Isolation and Analysis.
Advanced Clinical Chemistry, 1–31. doi: 10.1016/bs.acc.2016.03.003.

This review summarizes several methods of microfluidic CTC isolation and analysis, and
their applications in clinical studies. At its basest level, cancers are analyzed primarily by biopsy,
but this can be invasive and one-time tests. These microfluidic methods allow for fairly
non-invasive tests to be performed on a regular basis. While microfluidics can allow for smaller
blood samples, this also decreases the chance of a CTC to even be located in a blood sample, let
alone to be found.
The most widely used method is immunomagnetic separation. This entails enriching
CTCs based on the expression of surface proteins and capture agent-labeled magnetic beads
using cell-surface markers of depleting white blood cells. There is also isolation based on
physical properties, in which CTCs can be separated by such factors as size, density,
deformability, or electric charges. The methods for such consist of centrifugation, membrane- or
filtration-based systems, or dielectrophoresis (DEP). Another method is isolation by biological
properties, such as surface antigens, cytoplasmic protein expression, and invasion capacity. This
will entail typically adhering such biological systems to the CTCs and then detecting or
removing those biological systems. The paper then goes on to discuss how to analyze CTCs, but
that is not specifically relevant to this project, as we are mainly interested in the separation itself.
25) Adams André A., Okagbare, P. I., Feng, J., Hupert, M. L., Patterson, D., Göttert Jost, …
Soper, S. A. (2008). Highly Efficient Circulating Tumor Cell Isolation from Whole Blood and
Label-Free Enumeration Using Polymer-Based Microfluidics with an Integrated Conductivity
Sensor. Journal of the American Chemical Society, 130(27), 8633–8641. doi: 10.1021/ja8015022
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This article illustrates a potential antibody-based isolation method for breast cancer
CTCs. This allows larger volumes of blood (>1mL) to be filtered in a shorter time period (<37
minutes) that other microfluidic separators. This works by capturing the CTCs with antibodies,
then once they are released, counting them with an integrated conductivity sensor. The device
uses 51 high-aspect ratio microchannels covered in monoclonal antibodies to capture the
EpCAM segment of the CTCs. This allows for whole blood filtering, with an efficiency of over
97%.
While this device might not work with clusters of CTCs, this could be applicable to the
CD64 sepsis device, as that is also antibody based with minimal documentation. This device
releases the captured CTCs using trypsin, as well as devising a way to count the CTCs as they
pass, both of which could be used in our overall design.
26) Singer, K., Subbaiah, P., Hutchinson, R., Odetola, F., & Shanley, T. P. (2011). Clinical
course of sepsis in children with acute leukemia admitted to the pediatric intensive care unit.
Pediatric Critical Care Medicine, 12(6), 649–654. doi: 10.1097/pcc.0b013e31821927f1

While this article is mainly the abstract, we can still find relevance in a lot of the given
data. The goal of this article was to describe the clinical course, resource use, and mortality of
patients with leukemia admitted to the pediatric intensive care unit with sepsis and non-sepsis
diagnoses over a 10-yr period (1998-2008). The main point of this article was that patients with
acute leukemia and sepsis had a significantly higher mortality rate than standard pediatric sepsis
mortality rates. While this seems to be a fairly obvious conclusion, it does show how linked these
two diseases can be, and how deadly they can be. Treatments and their effectiveness was also
briefly discussed but that is not relevant to our device.
48.5% of the leukemia admissions additionally had sepsis upon admission. Additionally,
there was higher mortality among children with sepsis than other diagnoses (52% vs. 17%), and
mortality among children with sepsis was higher among those with acute lymphoblastic leukemia
(60% vs. 44%) compared to those with with acute myelogenous leukemia.
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27) DeAngelis, L. M. (2002). Leukemia and Lymphoma Metastases, 362–374. doi:
3601_e15_p362-374

This is one of the main articles on Leukemia metastasis. It describes statistics for CNS
metastasis and was one of my main sources on Leptomeningeal Metastasis (LM). Both leukemia
and lymphoma lead strongly into brain cancers, such as LM. LM can be particularly dangerous
because it can mimic vincristine peripheral neuropathy, which is common among patients with
lymphoma or leukemia. Patients with LM are also vulnerable to infections like sepsis, which can
mimic LM symptoms.
The paper also discusses the clinical features, diagnosis, initial management, and
treatment of epidural metastases (spinal cord) and LM (brain meninges). If a patient develops
LM, their prognosis is very grim, with a median survival of 6-10 months, depending on the type
of leukemia that created it. This is partially because LM is usually a late complication of
leukemia, but also because LM is immune to chemotherapy due to the blood-brain barrier, and
can cause spontaneous recurrence of cancer, typically in the brain.
28) Gauer, R. L. (2013). Early Recognition and Management of Sepsis in Adults: The First Six
Hours. American Family Physician, 88(1), 44–53. Retrieved from
https://www.aafp.org/afp/2013/0701/p44.html

This is one of the main articles for sepsis definition. Sepsis is a complication of severe
infection characterized by a systemic inflammatory response. It is life-threatening, extremely
common, aggressive, and displays a wide variety of symptoms, depending on the patient. Sepsis
can manifest with anything from cold/clammy skin to abdominal pain, to headache, sore throat,
chest pain, and many more. Basically any symptom of most common diseases, especially
infectious diseases, could be an indicator of sepsis, because it is triggered by infection. This can
make it very difficult to detect by physical symptoms alone.
The main symptoms of sepsis can be found within the body. Given that sepsis is a
combination of systemic inflammatory response syndrome (SIRS) and an infection we need to
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define what each of these are. While there are several different definition symptoms for SIRS,
the main one for our device is WBC count, specifically a white blood cell count > 12,000/mm3
or < 4,000/mm3. Additionally, we can define severe sepsis as sepsis with a platelet count <
100,000/mL. Early management is also discussed, being implemented within 6 hours of
suspected sepsis, and late management within the next six. We can see that the ideal window for
sepsis diagnosis is within 6-7 hours of first occurrence, though sooner is preferred.
29) Malik, I. A., Cardenas-Turanzas, M., Gaeta, S., Borthakur, G., Price, K., Cortes, J., & Nates,
J. L. (2017). Sepsis and Acute Myeloid Leukemia: A Population-Level Study of Comparative
Outcomes of Patients Discharged From Texas Hospitals. Clinical Lymphoma Myeloma and
Leukemia, 17(12). doi: 10.1016/j.clml.2017.07.009

This article displays statistics for adult leukemia patients, as well as how sepsis interacts
with adult leukemia, specifically acute myeloid leukemia (AML). Of these studied patients, 40%
were ≥ 65 years old, and 52% were men. Additionally, the rate of sepsis for AML patients was
16%, while it was only 4% for non-AML patients. Sepsis death was also 9% more common in
AML patients than non-AML patients (30% compared to 21%). The combination of increase in
sepsis incidence and mortality rates displays the need for rapid sepsis diagnosis in AML patients.
30) Bate, J., Gibson, F., Johnson, E., Selwood, K., Skinner, R., & Chisholm, J. (2013).
Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE
Clinical Guideline CG151). Archives of Disease in Childhood - Education & Practice Edition,
98(2), 73–75. doi: 10.1136/archdischild-2013-303634

This article has to do with neutropenic sepsis, which is “an abnormal decrease in the
number of neutrophils in the blood together with infection”. Neutropenic sepsis is also a
complication of anticancer treatments, and can be life-threatening. The mortality risk and other
risks of adverse clinical outcomes increase as the absolute neutrophil count (ANC) falls.
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Treatment is typically decided by a combination of neutrophil count and fever. Specifically, an
absolute neutrophil count of < 0.5 × 10^9 /litre, or < 1.0 × 10^9 /litre and falling.
This could have a huge impact on our project, given that we are planning to count a type
of neutrophil to determine sepsis. Given that the overall number of neutrophils will decrease
during neutropenic sepsis, it is safe to assume that the neutrophil type we are counting will also
decrease.
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